$4.29+0.39 (+10.00%)
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease.
Alterity Therapeutics Limited in the Healthcare sector is trading at $4.29. Wall Street consensus targets $12.00 (1 analysts), implying a +179.7% move over the next 12 months. The stock is currently 39% below its 52-week high of $7.00, remaining 9.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug ...
With the business potentially at an important milestone, we thought we'd take a closer look at Alterity Therapeutics...
Alterity Therapeutics (ATHE) said Thursday that data from a 77-patient phase 2 clinical trial of its
Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best performing ASX stocks in 2025. On September 15, the company shared data from its Phase 2 clinical trial of the drug ATH434-201 at the American Neurological Association Annual Meeting in Baltimore. The clinical trial involved people with Multiple System Atrophy (MSA), a rare brain condition that […]
Just because a business does not make any money, does not mean that the stock will go down. For example, Alterity...
Alterity Therapeutics Limited (NASDAQ:ATHE) is among the 12 Best Australian Stocks to Buy Right Now. The company recently reported positive topline data from an open-label Phase 2 clinical trial of ATH434-202 in individuals with multiple system atrophy (MSA). The trial involved evaluating patients with more advanced disease than studied earlier in the double-blind Phase 2 […]